Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Primary Immune Deficiency (PID) Pipeline Report, H2 2017 - Therapeutic Review of 15 Companies & Drug Profiles - Research and Markets

Research and Markets
Posted on: 12 Sep 17

The "Primary Immune Deficiency (PID) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Primary Immune Deficiency (PID) - Pipeline Review, H2 2017 provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Primary Immune Deficiency (PID) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 2, 8, 1, 6 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 5 and 2 molecules, respectively.

Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Primary Immune Deficiency (PID) - Overview
  3. Primary Immune Deficiency (PID) - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Primary Immune Deficiency (PID) - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Primary Immune Deficiency (PID) - Companies Involved in Therapeutics Development
  • ADMA Biologics Inc
  • Biotest AG
  • Casebia Therapeutics
  • Genethon SA
  • GigaGen Inc
  • GlaxoSmithKline Plc
  • Green Cross Corp
  • Leadiant Biosciences Inc
  • Novartis AG
  • Octapharma AG
  • ProMetic Life Sciences Inc
  • Sangamo Therapeutics Inc
  • Taiga Biotechnologies Inc
  • UCB SA
  • X4 Pharmaceuticals Inc

For more information about this report visit https://www.researchandmarkets.com/research/jm9xnb/primary_immune

View source version on businesswire.com: http://www.businesswire.com/news/home/20170912006569/en/

Business Wire
www.businesswire.com

Last updated on: 12/09/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.